AAAAAA

   
Results: 1-10 |
Results: 10
Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker
Authors: ten Berge, RL Oudejans, JJ Dukers, DF Meijer, JWR Ossenkoppele, GJ Meijer, CJLM
Citation: Rl. Ten Berge et al., Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker, LEUKEMIA, 15(3), 2001, pp. 458-464
Anaplastic large cell lymphoma: what's in a name?
Authors: Ten Berge, RL Oudejans, JJ Dukers, DF Meijer, CJLM
Citation: Rl. Ten Berge et al., Anaplastic large cell lymphoma: what's in a name?, J CLIN PATH, 54(6), 2001, pp. 494-495
All infiltrating T-lymphocytes in Hodgkin's disease express immunohistochemically detectable T-cell receptor zeta-chains in situ
Authors: Dukers, DF Oudejans, JJ Jaspars, EH Gras, M Vos, W Middeldorp, JM Meijer, CJLM Bloemena, E
Citation: Df. Dukers et al., All infiltrating T-lymphocytes in Hodgkin's disease express immunohistochemically detectable T-cell receptor zeta-chains in situ, HISTOPATHOL, 36(6), 2000, pp. 544-550
Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease
Authors: Dukers, DF Jaspars, LH Vos, W Oudejans, JJ Hayes, D Cillessen, S Middeldorp, JM Meijer, CJLM
Citation: Df. Dukers et al., Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease, J PATHOLOGY, 190(2), 2000, pp. 143-149
Rare occurrence of classical Hodgkin's disease as a T cell lymphoma
Authors: Muschen, M Rajewsky, K Brauninger, A Baur, AS Oudejans, JJ Roers, A Hansmann, ML Kuppers, R
Citation: M. Muschen et al., Rare occurrence of classical Hodgkin's disease as a T cell lymphoma, J EXP MED, 191(2), 2000, pp. 387-394
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occursbefore dissemination
Authors: ten Berge, RL Oudejans, JJ Ossenkoppele, GJ Pulford, K Willemze, R Falini, B Chott, A Meijer, CJLM
Citation: Rl. Ten Berge et al., ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occursbefore dissemination, J CLIN PATH, 53(6), 2000, pp. 445-450
Expression of Fas and Fas ligand in cutaneous B-cell lymphomas
Authors: Zoi-Toli, O Meijer, CJLM Oudejans, JJ De Vries, E Van Beek, P Willemze, R
Citation: O. Zoi-toli et al., Expression of Fas and Fas ligand in cutaneous B-cell lymphomas, J PATHOLOGY, 189(4), 1999, pp. 533-538
A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas
Authors: Dukers, DF ten Berge, RL Oudejans, JJ Pulford, K Hayes, D Misere, JFMM Ossenkoppele, GJ Jaspars, LH Willemze, R Meijer, CJLM
Citation: Df. Dukers et al., A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas, J CLIN PATH, 52(2), 1999, pp. 129-136
Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma
Authors: ten Berge, RL Dukers, DF Oudejans, JJ Pulford, K Ossenkoppele, GJ de Jong, D Misere, JFMM Meijer, CJLM
Citation: Rl. Ten Berge et al., Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma, BLOOD, 93(8), 1999, pp. 2688-2696
Untitled
Authors: Oudejans, JJ Dukers, DF ten Berge, RL Meijer, CJLM
Citation: Jj. Oudejans et al., Untitled, AM J PATH, 155(1), 1999, pp. 325-325
Risultati: 1-10 |